NIH Reporter #5K08AI182474-03

Machine Learning-Based Antibiotic Discovery Grant for Neisseria gonorrhoeae (NIAID)

This opportunity from the National Institute of Allergy and Infectious Diseases (NIAID) supports research into machine learning-driven antibiotic discovery for Neisseria gonorrhoeae, in partnership with Massachusetts General Hospital. - Government Buyer: - National Institute of Allergy and Infectious Diseases (NIAID) - Massachusetts General Hospital (Boston, MA) - Products/Services Requested: - Research and development activities focused on machine learning approaches to antibiotic discovery - In vitro and in vivo validation of novel therapeutic candidates - OEMs and Vendors: - No specific OEMs or commercial vendors are named; this is a research grant - Unique/Notable Requirements: - Emphasis on addressing multidrug resistance in Neisseria gonorrhoeae - Integration of machine learning techniques for drug discovery - Both laboratory and animal model validation required - Estimated Contract Value: - $196,738 - No special license or classification requirements noted - Standard NIH application process applies

Description

This NIH grant opportunity supports research on machine learning approaches to antibiotic discovery targeting Neisseria gonorrhoeae, with a focus on multidrug resistance. The project involves both in vitro and in vivo validation to develop novel therapeutic candidates. The research is conducted by Massachusetts General Hospital under the National Institute of Allergy and Infectious Diseases (NIAID). The solicitation follows the standard NIH application process.

View original listing